re: Ann: Pharmaxis Announces Positive Combine... Hi Stoss,You...

re: Ann: Pharmaxis Announces Positive Combine... Hi Stoss,

You have made a very important observation. Pulmozyme enjoys significant sales, has to be delivered by nebulizer which is messy and time consuming, and more importantly doesnt deliver the benefits of Bronchitol. The future certainly looks positive. We now just need a good response from the FDA.


http://www.stocknessmonster.com/news-item?S=PXS&E=ASX&N=596640


7/35


Current treatments: rhDNase and tobramycin

Delivered by nebulizer (preparation, sterilization)

rhDNase (Pulmozyme): global sales US$460mm (2009)

Tobramycin (Tobi): global sales US$233mm (2007)

18/35

Treatment burden a higher concern to
many families than reduced life expectancy

Twice a day dosing
2 - 5 minutes delivery time
Convenient and portable
Does not rely on a power source
No cleaning / maintenance/ sterilisation
required

wr
tu